ArQule is a biopharmaceutical company engaged in the research and development of therapeutics to treat cancers and rare diseases. Co.'s clinical pipeline includes: ARQ 531, which is a reversible dual inhibitor of both wild type and C481S-mutant Bruton's tyrosine kinase for B-cell malignancies refractory to other therapeutic options; Miransertib, which is a selective inhibitor of protein kinase B (AKT) in combination with the hormonal therapy, anastrozole; ARQ 751, which is a selective inhibitor of AKT for solid tumors harboring AKT, phosphoinositide 3-kinase or phosphatase and tensin homolog (PTEN) mutations or that are PTEN null; and Derazantinib, which is a multi-kinase inhibitor. The ARQL stock yearly return is shown above.
The yearly return on the ARQL stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ARQL annual return calculation with any dividends reinvested as applicable (on ex-dates).
|